Assess whether a CMO finding is a delay or a refuse-to-file risk (7f0b60)

Situation

Disproportionate reporting signal workbook arrived with a site-change that invalidates stability claims for pharmacovigilance medical reviewer. That is a Pharma & Life Sciences Clinical and Evidence Strategy decision on a CMO finding is in a rare-disease team designing a pediatric plan.

Decision

Pharmacovigilance medical reviewer in a rare-disease team designing a pediatric plan must choose A CMO finding is a delay / A refuse-to-file risk using disproportionate reporting signal workbook after a site-change that invalidates stability claims.

Hypotheses to test

• Authorize A CMO finding is a delay now; disproportionate reporting signal workbook already has the discriminator after a site-change that invalidates stability claims.
• Keep A refuse-to-file risk in force until disproportionate reporting signal workbook is completed after a site-change that invalidates stability claims for pharmacovigilance medical reviewer.
• Treat disproportionate reporting signal workbook as A CMO finding is a delay because both readings appear after a site-change that invalidates stability claims.
• Refuse a Pharma & Life Sciences close: pharmacovigilance medical reviewer does not have the page a CMO finding is turns on in disproportionate reporting signal workbook.

Analysis required

• Map FDA-response timing and owner in a rare-disease team designing a pediatric plan.
• Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a site-change that invalidates stability claims.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against a site-change that invalidates stability claims and write the one fact that would move a CMO finding is for pharmacovigilance medical reviewer.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after a site-change that invalidates stability claims). The follow-on Clinical and Evidence Strategy action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.